A phase I study of oral dissolving strips for the delivery of Isoniazid in children and adults.
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Isoniazid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacokinetics
- 06 Oct 2017 New trial record
- 03 Oct 2017 According to an Oak Therapeutics media release, the Oak therapeutics received Small Business Innovative Research (SBIR) contract from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) for this Phase I project.